



#3

Express Mail No.: EL 071 856 666 US**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Siegall et al.

Serial No.: 09/328,296

Examiner: To be assigned

Filed: June 8, 1999

Group Art Unit: 1642

For: RECOMBINANT ANTI-CD40 ANTIBODY AND  
USES THEREOF Attorney Docket No.: 9632-005**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. § 1.56 and § 1.97**Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby direct the Examiner's attention to the references (AA-BH) listed on the attached revised form PTO 1449 entitled "List of References Cited by Applicant". Copies of references AA-BH are submitted herewith.


Identification of the listed references is not to be construed an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application. Consequently, Applicants respectfully decline to use form PTO-1449, since this form identifies all of the references cited therein as "Prior Art". As an alternative, Applicants submit herewith several pages of a "revised form PTO 1449" entitled "List of References Cited" instead of "List of Prior Art Cited".

Pursuant to 37 C.F.R. § 1.97(b)(3), since Applicants believe that this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits, no fee is due. However, should the Patent Office determine otherwise, please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A duplicate of this sheet is enclosed for accounting purposes.

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

Respectfully submitted,

Date: September 30, 1999

  
Adriane M. Antler 32,605  
(Reg. No.)

**PENNIE & EDMONDS LLP**  
1155 Avenue of the Americas  
New York, New York 10036-2711  
(212) 790-9090



LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)					ATTY. DOCKET NO. 9632-005		APPLICATION NO. 09/328,296	
					APPLICANT Siegall et al.			
					FILING DATE 06/08/99		GROUP 1642	
<b>U.S. PATENT DOCUMENTS</b>								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	AA	5,182,368	01/26/93	Ledbetter et al.	530	388.73		
	AB	5,674,492	10/07/97	Armitage et al.	424	144.1		
	AC	5,677,165	09/16/97	de Boer et al.	242	588.2		
<b>FOREIGN PATENT DOCUMENTS</b>								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AD	WO 96/18413		PCT				
<b>OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)</b>								
	AE	Armitage et al., "Distinct patterns of inhibition by CD40 mAb of the CD40 ligand-CD40 interaction", in <u>Leukocyte Typing V</u> , Schlossman et al. (Eds.) 1995; 1: 551-552.						
	AF	Bubenik J et al., "Monoclonal antibodies against human urinary bladder carcinomas: selectivity and utilization for gamma scintigraphy", Eur J Cancer Clin Oncol. 1985 Jun;21(6):701-10.						
	AG	Challa A et al., "Epitope-dependent synergism and antagonism between CD40 antibodies and soluble CD40 ligand for the regulation of CD23 expression and IgE synthesis in human B cells", Allergy. 1999 Jun;54(6):576-83.						
	AH	Clark EA and Ledbetter JA, "Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50", Proc Natl Acad Sci U S A. 1986 Jun;83(12):4494-8.						
	AI	De Paoli P, "High CD40 membrane expression in AIDS-related lymphoma B cell lines is associated with the CD45RA+, CD45RO+, CD95+ phenotype and high levels of its soluble form in culture supernatants", Cytometry. 1997 Feb 15;30(1):33-8.						
	AJ	Fanslow et al., "CD40 mAb M2 and M3 inhibit CD40 ligand binding and function", in <u>Leukocyte Typing V</u> , Schlossman et al. (Eds.) 1995; 1: 555-556.						
	AK	Francisco JA et al., "Construction, expression, and characterization of BD1-G28-5 sFv, a single-chain anti-CD40 immunotoxin containing the ribosome-inactivating protein bryodin 1", J Biol Chem. 1997 Sep 26;272(39):24165-9.						
	AL	Funakoshi S et al., "Inhibition of human B-cell lymphoma growth by CD40 stimulation", Blood. 1994 May 15;83(10):2787-94.						
	AM	Funakoshi S et al., "Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas", J Immunother Emphasis Tumor Immunol. 1996 Mar;19(2):93-101.						



AN	Gilliland LK et al., "Rapid and reliable cloning of antibody variable regions and generation of recombinant single chain antibody fragments", Tissue Antigens. 1996 Jan;47(1):1-20.
AO	Grafton G et al., "Mechanisms of antigen receptor-dependent apoptosis of human B lymphoma cells probed with a panel of 27 monoclonal antibodies", Cell Immunol. 1997 Nov 25;182(1):45-56.
AP	Grewal IS and Flavell RA, "CD40 and CD154 in cell-mediated immunity", Annu Rev Immunol. 1998;16:111-35.
AQ	Herbert and Callard, "Inhibition of specific antibody production by CD40L and a panel of antibodies to CD40", in <u>Leukocyte Typing V</u> , Schlossman et al. (Eds.) 1995; 1:552-554.
AR	Katira et al., "CD40 Workshop Panel report", in <u>Leukocyte Typing V</u> , Schlossman et al. (Eds.) 1995; 1: 547-550.
AS	Katira et al., "Identification of co-operative epitopes on CD40 supports the existence of a second CD40 ligand", in <u>Leukocyte Typing V</u> , Schlossman et al. (Eds.) 1995; 1: 554.
AT	Kawabe et al., "Generation and characterization of CD40-deficient mice", in <u>Leukocyte Typing V</u> , Schlossman et al. (Eds.) 1995; 1: 550-551.
AU	Kehry MR. CD40-mediated signaling in B cells. Balancing cell survival, growth, and death", J Immunol. 1996 Apr 1;156(7):2345-8.
AV	Koho H et al., "Monoclonal antibodies to antigens associated with transitional cell carcinoma of the human urinary bladder. I. Determination of the selectivity of six antibodies by cell ELISA and immunofluorescence", Cancer Immunol Immunother. 1984;17(3):165-72.
AW	Kuhne MR et al., "Assembly and regulation of the CD40 receptor complex in human B cells", J Exp Med. 1997 Jul 21;186(2):337-42.
AX	Malik N et al., "Activation of human monocytes through CD40 induces matrix metalloproteinases", J Immunol. 1996 May 15;156(10):3952-60.
AY	Murphy WJ et al., "Antibodies to CD40 prevent Epstein-Barr virus-mediated human B-cell lymphomagenesis in severe combined immune deficient mice given human peripheral blood lymphocytes", Blood. 1995 Sep 1;86(5):1946-53.
AZ	Noelle RJ et al., "A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells", Proc Natl Acad Sci U S A. 1992 Jul 15;89(14):6550-4.
BA	Paulie S et al., "The human B lymphocyte and carcinoma antigen, CDw40, is a phosphoprotein involved in growth signal transduction", J Immunol. 1989 Jan 15;142(2):590-5.
BB	Pound JD et al, "Minimal cross-linking and epitope requirements for CD40-dependent suppression of apoptosis contrast with those for promotion of the cell cycle and homotypic adhesions in human B cells", Int Immunol 1999 Jan;11(1):11-20.
BC	Speiser DE et al., "A regulatory role for TRAF1 in antigen-induced apoptosis of T cells", J Exp Med. 1997 May 19;185(10):1777-83.
BD	Stamenkovic I et al., "A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas", EMBO J. 1989 May;8(5):1403-10.
BE	Tutt AL et al., "Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors", J Immunol. 1998 Sep 15;161(6):3176-85.
BF	van Kooten C and Banchereau J, "Functions of CD40 on B cells, dendritic cells and other cells", Curr Opin Immunol. 1997 Jun;9(3):330-7.

	BG	Yeh WC et al., "Early lethality, functional NF-kappaB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice", Immunity. 1997 Nov;7(5):715-25.
	BH	Younes A et al., "Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemia", Br J Haematol. 1998 Jan;100(1):135-41.
EXAMINER		DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with <b>MPEP 609</b> ; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

